BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease
October 04, 2017 at 06:00 AM EDT
* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018